Patient characteristics and response to treatment according to CRLF2 expression in 555 patients with childhood precursor B-cell acute lymphoblastic leukemia
| . | CRLF2 low, n (%) . | CRLF2 high, n (%) . | P* . |
|---|---|---|---|
| Number of patients | 506 (100) | 49 (100) | |
| Down syndrome | < .001 | ||
| Yes | 7 (1.4) | 7 (14.2) | |
| No | 499 (98.6) | 42 (85.8) | |
| Sex | .65 | ||
| Male | 267 (52.8) | 24 (49.0) | |
| Female | 239 (47.2) | 25 (51.0) | |
| Age at diagnosis, y | .30 | ||
| 1 to less than 10 | 375 (74.1) | 40 (81.6) | |
| 10 or older | 131 (25.9) | 9 (18.4) | |
| Presenting WBC count, cells/μL | .23 | ||
| Less than 10 000 | 168 (33.2) | 16 (32.7) | |
| 10 000 to less than 50 000 | 223 (44.1) | 19 (38.8) | |
| 50 000 to less than 100 000 | 70 (13.8) | 5 (10.2) | |
| More than 100 000 | 45 (8.9) | 9 (18.4) | |
| BCR/ABL | .19 | ||
| Positive | 7 (1.4) | 2 (4.1) | |
| Negative | 499 (98.6) | 47 (95.9) | |
| MLL/AF4 | > .999 | ||
| Positive | 5 (1.0) | 0 (0.0) | |
| Negative | 501 (99.0) | 49 (100.0) | |
| TEL/AML1 | < .001 | ||
| Positive | 146 (28.9) | 0 (0.0) | |
| Negative | 345 (68.2) | 45 (90.5) | |
| Unknown | 15 (2.9) | 4 (9.5) | |
| NCI risk group | .76 | ||
| Standard | 295 (58.3) | 30 (61.2) | |
| High | 211 (41.7) | 19 (38.8) | |
| Prednisone response† | > .999 | ||
| Good | 466 (92.1) | 46 (93.9) | |
| Poor | 38 (7.5) | 3 (6.1) | |
| No result | 2 (0.4) | 0 (0.0) | |
| MRD‡ | .42 | ||
| Less than 10−3 | 462 (91.3) | 42 (85.7) | |
| More than 10−3 | 19 (3.8) | 3 (6.1) | |
| No result | 25 (4.9) | 4 (8.2) |
| . | CRLF2 low, n (%) . | CRLF2 high, n (%) . | P* . |
|---|---|---|---|
| Number of patients | 506 (100) | 49 (100) | |
| Down syndrome | < .001 | ||
| Yes | 7 (1.4) | 7 (14.2) | |
| No | 499 (98.6) | 42 (85.8) | |
| Sex | .65 | ||
| Male | 267 (52.8) | 24 (49.0) | |
| Female | 239 (47.2) | 25 (51.0) | |
| Age at diagnosis, y | .30 | ||
| 1 to less than 10 | 375 (74.1) | 40 (81.6) | |
| 10 or older | 131 (25.9) | 9 (18.4) | |
| Presenting WBC count, cells/μL | .23 | ||
| Less than 10 000 | 168 (33.2) | 16 (32.7) | |
| 10 000 to less than 50 000 | 223 (44.1) | 19 (38.8) | |
| 50 000 to less than 100 000 | 70 (13.8) | 5 (10.2) | |
| More than 100 000 | 45 (8.9) | 9 (18.4) | |
| BCR/ABL | .19 | ||
| Positive | 7 (1.4) | 2 (4.1) | |
| Negative | 499 (98.6) | 47 (95.9) | |
| MLL/AF4 | > .999 | ||
| Positive | 5 (1.0) | 0 (0.0) | |
| Negative | 501 (99.0) | 49 (100.0) | |
| TEL/AML1 | < .001 | ||
| Positive | 146 (28.9) | 0 (0.0) | |
| Negative | 345 (68.2) | 45 (90.5) | |
| Unknown | 15 (2.9) | 4 (9.5) | |
| NCI risk group | .76 | ||
| Standard | 295 (58.3) | 30 (61.2) | |
| High | 211 (41.7) | 19 (38.8) | |
| Prednisone response† | > .999 | ||
| Good | 466 (92.1) | 46 (93.9) | |
| Poor | 38 (7.5) | 3 (6.1) | |
| No result | 2 (0.4) | 0 (0.0) | |
| MRD‡ | .42 | ||
| Less than 10−3 | 462 (91.3) | 42 (85.7) | |
| More than 10−3 | 19 (3.8) | 3 (6.1) | |
| No result | 25 (4.9) | 4 (8.2) |
MRD indicates minimal residual disease; NCI, National Cancer Institute; and WBC, white blood cell.
Fisher exact test comparing the CRLF2 high and CRLF2 low groups.
Good: < 1000 leukemic blood blasts/μL on treatment day 8; poor: > 1000/μL.
After induction consolidation at week 12, MRD > 10−3 qualifies for the high-risk group.